Figure S6. Observed incidence and predicted probability of grade ≥ 3 AEs of interest as a function of time-averaged brigatinib AUC to the first occurrence of an event or the end of treatment in case of no event using a logistic regression model. AEs were included in the analysis if they occurred from the first day of brigatinib dosing until 30 days after the last dose. The relationship between time-averaged exposure and AE probability was examined using the same logistic regression models described for the exposure–clinical response analyses. No clear trend was shown for a relationship with any of the AEs evaluated, with the exception of a weak trend for grade ≥ 3 lipase increase.

Note: Any AE included CPK, AST, ALT, amylase, lipase, hyperglycemia, hypertension, bradycardia, rash and pulmonary events

AE adverse event, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *AUC* area under the concentration-time curve, *CI* confidence interval, *CPK* creatine phosphokinase, *OBS* observed